Federal Register / Vol. 87, No. 45 / Tuesday, March 8, 2022 / Notices 12967 

• HIV prevention services: Voluntary 

medical male circumcision; Cervical 

cancer prevention and treatment; 

Gender based violence Prevention and 

response; Condom programming; Preexposure prophylaxis; Elimination of 

mother-to-child transmission; Support 

for Key and vulnerable populations and 

Orphans and vulnerable children; 

• HIV treatment and support services 

for all age groups across the care 

continuum from case finding to viral 

load suppression. Support will include: 

Prevention and management of 

opportunistic infections and advanced 

HIV disease, as well as noncommunicable diseases (including 

support for mental health); 

• Health system strengthening 

including support to financial and 

administrative management systems, 

internal controls, human resources for 

health, health information systems, 

supply chain/commodities 

management, laboratory services, and 

continuous quality improvement. 

The Provincial Health Offices are the 

single entities eligible for this award 

since they are the sole government 

institutions with the mandate to support 

health service delivery through capacity 

building, systems strengthening, and 

oversight for HIV program 

implementation for the population of 

Zambia per the National Health Policy 

and Zambian National Health Strategic 

Plan. 

Summary of the Award 

Recipient: Southern Provincial Health 

Office; Lusaka Provincial Health Office; 

Western Provincial Health Office; and 

Eastern Provincial Health Office in 

Zambia. 

Purpose of the Award: The purpose of 

this award is to provide PHOs with CDC 

technical assistance and financial 

support to maintain and sustain the 

province’s overall leadership and 

oversight for implementing high-impact 

HIV combination prevention, treatment, 

and support services, including clinical, 

surveillance, and laboratory services as 

well as to identify and mitigate 

emerging disease threats for PLHIV. 

Specifically, it will serve to strengthen 

capacity development activities, while 

providing optimal health systems 

strengthening in support of continued 

and sustainable HIV epidemic control in 

Zambia. 

Amount of Award: The approximate 

year 1 funding amount in Federal Fiscal 

Year (FFY) 2022 funds will be, subject 

to the availability of funds: 

• Southern Provincial Health Office 

(SPHO): Anticipated Year 1 Funding 

Amount is $14,500,000 

• Lusaka Provincial Health Office 

(LPHO): Anticipated Year 1 Funding 

Amount is $19,000,000 

• Western Provincial Health Office 

(WPHO): Anticipated Year 1 Funding 

Amount is $12,000,000 

• Eastern Provincial Health Office 

(EPHO): Anticipated Year 1 Funding 

Amount is $12,000,000; 

Funding amounts for years 2–5 will be 

set at continuation. 

Authority:This program is authorized 

under Public Law 108–25 (the United 

States Leadership Against HIV AIDS, 

Tuberculosis and Malaria Act of 2003). 

Period of Performance: September 30, 

2022, through September 29, 2027. 

Dated: March 2, 2022. 

Terrance Perry, 

Chief Grants Management Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2022–04827 Filed 3–7–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Single-Source 

Cooperative Agreement To Fund the 

National AIDS Control Committee 

(NACC), Cameroon 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $3,000,000 for 

Year 1 of funding to the National AIDS 

Control Committee (NACC), Cameroon. 

The award will strengthen national 

policies, build capacity, and define 

high-level high-impact interventions 

and key strategies for HIV/TB 

prevention, treatment and care in 

Cameroon. Funding amounts for years 

2–5 will be set at continuation. 

DATES: The period for this award will be 

September 30, 2022, through September 

29, 2027. 

FOR FURTHER INFORMATION CONTACT: Lisa 

Esapa, Center for Global Health, Centers 

for Disease Control and Prevention, 

Standard Chartered Bank Building, 

Hippodrome, Telephone: 800–232– 

6348, Email: hww5@cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

single-source award will implement HIV 

prevention, care and treatment in 

Cameroon through activities, including: 

Developing and implementing policies 

and strategies to optimize case finding, 

HIV treatment and retention, viral load 

coverage and suppression, and building 

workforce capacity to improve uptake 

and quality of these HIV/TB services; 

and enhancing the implementation of 

evidence-based prevention 

interventions for KPs (key populations) 

/PPs (priority populations) /GP (general 

populations. Implementation of this 

award will enhance scale up of services 

and improve quality of diagnostics, 

treatment, management, and clinical 

outcomes for HIV and TB infections in 

Cameroon. This award will build upon 

CDC’s initial successful partnerships to 

address these challenges and gaps and 

complement Global Fund efforts. NACC 

is in a unique position to conduct this 

work, as it is the organization mandated 

by the Government of Cameroon to 

coordinate HIV/AIDS activities in 

Cameroon. NACC is essential to 

building effective national-level 

coordination in HIV programs, as 

mandated in the 2000–2005 and 2006– 

2010 National HIV/AIDS Strategic 

Plans. The mission of NACC is to 

coordinate a comprehensive and 

effective multi-sector and decentralized 

national response to HIV/AIDS, 

including coordination and support to 

the health sector response. 

Summary of the Award 

Recipient: National AIDS Control 

Committee (NACC), Cameroon. 

Purpose of the Award: The purpose of 

this award is to strengthen national 

policies and define high-level highimpact interventions and key strategies 

for HIV/TB prevention, treatment and 

care; improve knowledge and prevent 

high risk behaviors associated with 

STIs/HIV; monitor and ensure the 

elimination of user fees for all HIV/TB 

services; develop national quality 

improvement policy and setup CQI 

management system; provide technical 

capacity to generate quality data; reduce 

HIV/TB related morbidity and mortality; 

and provide capacity to coordinate and 

monitor the national HIV response in 

Cameroon. 

Amount of Award: The approximate 

year 1 funding amount will be $ 

3,000,000 in Federal Fiscal Year (FYY) 

2022 funds, subject to the availability of 

funds. Funding amounts years 2–5 will 

be set at continuation. 

Authority: This program is authorized 

under Public Law 108–25 (the United 

States Leadership Against HIV AIDS, 

Tuberculosis and Malaria Act of 2003). 

Period of Performance: September 30, 

2022, through September 29, 2027. 


lotter on DSK11XQN23PROD with NOTICES1
12968 Federal Register / Vol. 87, No. 45 / Tuesday, March 8, 2022 / Notices 

Dated: March 2, 2022. 

Terrance Perry, 

Chief Grants Management Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2022–04788 Filed 3–7–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: NCGC00413972 and Its 

Related Analogs Consisting of an 

Imidazo-Pyrazine Scaffold Core for the 

Treatment or Prevention of Cancers 

Expressing the Mannose Receptor 

CD206, Including Both Solid Tumors 

and Hematological Malignancies 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patent Applications listed in the 

SUPPLEMENTARY INFORMATION section of 

this notice to Macala Bio, Inc. located in 

1000 NW Wall Street, Suite 220, Bend, 

OR 97703. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before March 23, 2022 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Eric Cheng, Ph.D., Licensing 

and Patenting Manager at (240)-276– 

5530 or eric.cheng2@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

United States Provisional Patent 

Application No. 62/950,488, filed 19 

December 2019 and entitled ‘‘CD206 

Modulators Their Use And Methods For 

Preparation’’ [HHS Reference No. E– 

105–2019/0–US–01]; 

PCT Patent Application PCT/US2020/ 

065238, filed 16 December 2020 and 

entitled ‘‘CD206 Modulators Their Use 

And Methods For Preparation’’ [HHS 

Reference No. E–105–2019–0–PCT–02]. 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to: 

NCGC00413972 and its related analogs 

consisting of an imidazo-pyrazine 

scaffold core for the treatment or 

prevention of cancers expressing the 

mannose receptor CD206, including 

both solid tumors and hematological 

malignancies. 

This technology discloses 

immunotherapy drugs, and to 

compounds that modulate CD206 as 

well as their use and methods for 

preparation. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: March 2, 2022. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2022–04829 Filed 3–7–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request Generic Clearance 

for National Cancer Institute (NCI) NCI 

Resources, Software and Data Sharing 

Forms (National Cancer Institute) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, the 

National Institutes of Health (NIH) has 

submitted to the Office of Management 

and Budget (OMB) a request for review 

and approval of the information 

collection listed below. 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 30-days of the date of this 

publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments, submit 

comments in writing, or request more 

information on the proposed project, 

contact: Diane Kreinbrink, Office of 

Management Policy and Compliance, 

National Cancer Institute, 9609 Medical 

Center Drive, Rockville, Maryland, 208 

or call non-toll-free number (240) 276– 

7283 or email your request, including 

your address to: diane.kreinbrink@

nih.gov. Formal requests for additional 

plans and instruments must be 

requested in writing. 

SUPPLEMENTARY INFORMATION: This 

proposed information collection was 

previously published in the Federal 

Register on December 20, 2021 (Vol. 86 

FR 71901) and allowed 60 days for 

public comment. No public comments 

were received. The purpose of this 

notice is to allow an additional 30 days 

for public comment. The National 

Cancer Institute (NCI), National 

Institutes of Health (NIH), may not 

conduct or sponsor, and the respondent 

is not required to respond to, an 

information collection that has been 

extended, revised, or implemented on or 

after October 1, 1995, unless it displays 

a currently valid Office of Management 

and Budget (OMB) control number. 

In compliance with Section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, NIH has 

submitted to OMB a request for review 

and approval of the information 

collection listed below. 

Proposed Collection: Generic 

Clearance for NCI Resources, Software 

and Data Sharing Forms, 0925—NEW, 

Expiration Date xx/xx/xxxx, NCI, NIH. 

Need and Use of Information 

Collection: In preparation for 

dissemination and sharing of data sets, 

forms requesting or applying for access, 

upload, share, and store data will be 

needed. The purpose of data sharing 


lotter on DSK11XQN23PROD with NOTICES1